Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
Massachusetts | | 001-14041 | | 04-2882273 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | | | | | |
125 Summer Street, Boston, MA | | 02110 |
(Address of principal executive offices) | | (Zip Code) |
| | |
James C. D’Arecca Executive Vice President, Chief Financial Officer (781) 848-7100 |
(Name and telephone number, including area code, of the person to contact in connection with this report) |
| | | | | |
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies: |
| |
☒ | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2023. |
| |
☐ | Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended. |
SECTION 1 - Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, Haemonetics Corporation (the “Company”) has filed this Form SD for the reporting period from January 1, 2023 to December 31, 2023.
A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is publicly available at http://www.haemonetics.com/about-us/corporate-responsibility/conflict-minerals-statement. The information contained on our website is not incorporated by reference into this Form SD or our Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.
Item 1.02 Exhibit
Item 3.01 of this Form SD is incorporated by reference into this Item 1.02.
SECTION 3 - Exhibits
Item 3.01 Exhibits
| | | | | | | | |
Exhibit Number | | Description |
| | Conflict Minerals Report of Haemonetics Corporation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | |
| | | | |
| | HAEMONETICS CORPORATION | |
| | | | |
Date: May 28, 2024 | | By: | /s/ James C. D’Arecca | |
| | Name: | James C. D’Arecca | |
| | Title: | Executive Vice President, Chief Financial Officer |
| | | | |